Harbin Gloria Pharmaceuticals (002437) — Financial Flexibility Index
Harbin Gloria Pharmaceuticals (002437) has a Financial Flexibility Index of 0.22x as of September 2025. Free cash flow of CN¥187.15 Million (operating CF CN¥182.89 Million minus capex CN¥4.26 Million) represents 0% of total liabilities (CN¥852.18 Million). Check cash flow reinvestment rate of Harbin Gloria Pharmaceuticals to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Harbin Gloria Pharmaceuticals Financial Flexibility Index (2007–2025)
Historical Financial Flexibility Index trend for Harbin Gloria Pharmaceuticals across 19 annual periods. For the full cash flow conversion analysis, see Harbin Gloria Pharmaceuticals cash flow conversion.
Annual Financial Flexibility Index for Harbin Gloria Pharmaceuticals (2007–2025)
Year-by-year free cash flow to debt coverage for Harbin Gloria Pharmaceuticals. Explore Harbin Gloria Pharmaceuticals (002437) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.36x | CN¥297.17 Million | CN¥273.36 Million | CN¥825.00 Million | ▼ -35.2% |
| 2024 | 0.56x | CN¥473.83 Million | CN¥410.94 Million | CN¥852.26 Million | ▲ +163.9% |
| 2023 | 0.21x | CN¥303.80 Million | CN¥274.18 Million | CN¥1.44 Billion | ▲ +69.5% |
| 2022 | 0.12x | CN¥294.63 Million | CN¥261.62 Million | CN¥2.37 Billion | ▲ +9.4% |
| 2021 | 0.11x | CN¥308.69 Million | CN¥274.18 Million | CN¥2.72 Billion | ▲ +420.3% |
| 2020 | 0.02x | CN¥56.43 Million | CN¥12.76 Million | CN¥2.58 Billion | ▼ -84.0% |
| 2019 | 0.14x | CN¥658.79 Million | CN¥610.37 Million | CN¥4.82 Billion | ▼ -45.2% |
| 2018 | 0.25x | CN¥1.27 Billion | CN¥1.16 Billion | CN¥5.08 Billion | ▲ +41.7% |
| 2017 | 0.18x | CN¥846.43 Million | CN¥651.80 Million | CN¥4.81 Billion | ▼ -33.7% |
| 2016 | 0.27x | CN¥1.23 Billion | CN¥1.04 Billion | CN¥4.62 Billion | ▲ +30.5% |
| 2015 | 0.20x | CN¥985.14 Million | CN¥702.05 Million | CN¥4.85 Billion | ▼ -53.7% |
| 2014 | 0.44x | CN¥799.93 Million | CN¥674.04 Million | CN¥1.82 Billion | ▼ -66.9% |
| 2013 | 1.33x | CN¥616.37 Million | CN¥453.02 Million | CN¥464.60 Million | ▼ -22.8% |
| 2012 | 1.72x | CN¥350.25 Million | CN¥205.89 Million | CN¥203.79 Million | ▼ -33.2% |
| 2011 | 2.57x | CN¥295.51 Million | CN¥128.61 Million | CN¥114.91 Million | ▼ -46.4% |
| 2010 | 4.79x | CN¥353.47 Million | CN¥112.59 Million | CN¥73.73 Million | ▲ +219.8% |
| 2009 | 1.50x | CN¥232.29 Million | CN¥170.82 Million | CN¥154.95 Million | ▲ +33.2% |
| 2008 | 1.13x | CN¥95.89 Million | CN¥57.81 Million | CN¥85.17 Million | ▲ +32.7% |
| 2007 | 0.85x | CN¥65.44 Million | CN¥52.26 Million | CN¥77.15 Million | — |